Research programme: skin disorders therapy - Medicis Pharmaceutical Corporation
Latest Information Update: 10 Mar 2010
At a glance
- Originator Medicis Pharmaceutical Corporation
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 23 Mar 2009 Preclinical development appears to be ongoing in the US